Ionis Pharmaceuticals IONS Debt Securities, Available-for-Sale, Unrealized Loss Position
Debt Securities, Available-for-Sale, Unrealized Loss Position at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt securities, available-for-sale, unrealized loss position.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt securities, available-for-sale, unrealized loss position?
- Ionis Pharmaceuticals (IONS) reported debt securities, available-for-sale, unrealized loss position of $1.03B in Q1 2026.
- How has Ionis Pharmaceuticals's debt securities, available-for-sale, unrealized loss position changed year-over-year?
- Ionis Pharmaceuticals's debt securities, available-for-sale, unrealized loss position increased by 28.1% year-over-year, from $806.7M to $1.03B.